UK lung cancer study demonstrates further evidence on importance of CT screening
Currently the third most common cancer in the UK, lung cancer affects 40,000 people annually
Read Moreby Jen Brogan | May 22, 2024 | News | 0
Currently the third most common cancer in the UK, lung cancer affects 40,000 people annually
Read Moreby John Pinching | Dec 20, 2022 | News | 0
Therapy shows quality of life boost and significant improvement in lung function
Read Moreby John Pinching | Jul 27, 2022 | News | 0
First carbon minimal pMDI is on track with the joint goal of benefitting patients and the planet
Read Moreby John Pinching | Jun 10, 2022 | News | 0
The company completes its enrolment in phase 3 trial evaluating ensifentrine for treatment of COPD
Read Moreby Selina McKee | Dec 14, 2020 | News | 0
The triple combination therapy Trixeo Aerosphere cut the rate of moderate or severe exacerbations compared with dual-combination therapies in clinical trials
Read Moreby Lucy Parsons | Sep 24, 2020 | News | 0
Phase III trial programme will evaluate nebulised ensifentrine in moderate-to-severe COPD
Read Moreby Selina McKee | Sep 10, 2020 | News | 0
Trelegy Ellipta is now the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US
Read Moreby Selina McKee | Aug 19, 2020 | News | 0
Following a pause because of coronavirus, the company has now kicked off the second part of a trial assessing a pressurised metered-dose inhaler formulation of ensifentrine
Read Moreby Selina McKee | Jul 24, 2020 | News | 0
Breztri Aerosphere is also under regulatory review in the EU
Read Moreby Selina McKee | Jun 25, 2020 | News | 0
The triple therapy is currently under review for COPD in both the EU and US
Read Moreby Anna Smith | Feb 14, 2020 | News | 0
Ensifentrine showed clinically and statistically significant improvements in lung function at all doses.
Read Moreby Anna Smith | Sep 17, 2019 | News | 0
Pharmacists are likely to see people with COPD and asthma more regularly than a GP or nurse, so they play a pivotal role in educating patients on their medicines and inhaler technique.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479